HAMBURG, Germany – Edwards Lifesciences Corp. received U.S. FDA approval to market its Sapien 3 Ultra system for transcatheter aortic valve replacement in severe, symptomatic aortic stenosis patients who are at intermediate or greater risk of open-heart surgery.